Overview

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality. The investigators hypothesize that a go-slow gentle approach to starting treatment in such patients, starting with just Isatuximab and dexamethasone with a gentle introduction to lenalidomide third cycle onwards, may improve treatment adherence and quality of life. The goal of this clinical trial is to learn if a go-slow approach to treating MM in ultra-frail patients may improve the ability to adhere to treatment and improve quality of life.

Phase:

PHASE2

Details

Lead Sponsor:

University of Utah

Collaborator:

Sanofi

Treatments:

Dexamethasone
isatuximab
Lenalidomide